Video Capsule Endoscopy to Investigate the Safety and Tolerability of Lumiracoxib in the Small Bowel

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

This study is designed to investigate the potential differences in GI safety and tolerability in the small bowel between lumiracoxib, conventional non-selective NSAID (naproxen) with a proton pump inhibitor (omeprazole), or placebo.

• Phase: Phase 4

Details

• Lead Sponsor: Novartis
• Treatments: Diclofenac; Lumiracoxib; Naproxen; Omeprazole

Criteria

Inclusion Criteria:

• Healthy male or female subjects

Exclusion Criteria:

• Evidence of cardiovascular, hepatic, gastrointestinal or renal disorders

• Hereditary problems of galactose intolerance, a severe lactase deficiency or glucose-galactose malabsorption syndrome

• Smokers

Other protocol-defined inclusion/exclusion criteria may apply